# JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07336823/  
OnCo record `nct07336823` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of JY232 run by Shenzhen Genocury Biotech Co., Ltd., now recruiting.

## Summary

JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT07336823 by Shenzhen Genocury Biotech Co., Ltd., with 9 participants planned, started 2026-01-20, primary completion expected 2028-12-31. Conditions recorded: Multiple Myeloma. Interventions recorded: JY232 Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07336823
- Phase: 1
- Setting: A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of JY232 Injection in Patients With Relapsed/Refractory Multiple Myeloma
- Sponsor: Shenzhen Genocury Biotech Co., Ltd.
- Enrolled: 9

## Sources

- ClinicalTrials.gov NCT07336823: https://clinicaltrials.gov/study/NCT07336823

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [JY232](https://onco.cc/drugs/jy232/)
- companies: [Genocury Biotech](https://onco.cc/companies/genocury-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07336823.json